We are live on
!
Find out more
QC
Quadrature Capital Portfolio holdings
AUM
$11.7B
1-Year Est. Return
87.29%
This Fund
S&P 500
This Quarter
Est. Return
-2.54%
1 Year Est. Return
+87.29%
3 Year Est. Return
+211.84%
5 Year Est. Return
+162.22%
10 Year Est. Return
+656.25%
AUM
$4.51B
AUM Growth
-$481M
(-9.6%)
Cap. Flow
-$244M
Cap. Flow
% of AUM
-5.41%
Top 10 Holdings %
Top 10 Hldgs %
25.07%
Holding
1,566
New
582
Increased
206
Reduced
242
Closed
534
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$243M |
| 2 |
Canadian National Railway
CNI
|
+$116M |
| 3 |
State Street Materials Select Sector SPDR ETF
XLB
|
+$99M |
| 4 |
Stellantis
STLA
|
+$87.2M |
| 5 |
Canadian Natural Resources
CNQ
|
+$75.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$182M |
| 2 |
Tesla
TSLA
|
+$165M |
| 3 |
Ferrari
RACE
|
+$145M |
| 4 |
Elevance Health
ELV
|
+$118M |
| 5 |
UnitedHealth
UNH
|
+$111M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.4% |
| 2 | Financials | 12.65% |
| 3 | Industrials | 10.78% |
| 4 | Communication Services | 8.14% |
| 5 | Consumer Discretionary | 7.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
INZY
1001
DELISTED
Inozyme Pharma
INZY
| $35.5K | ﹤0.01% |
+39,496
| New | +$54.7K |
|
1002
ProQR Therapeutics
PRQR
$255M
| $35.4K | ﹤0.01% |
+26,403
| New | +$56.2K |
|
|
BORR
1003
Borr Drilling
BORR
$1.28B
| $34.9K | ﹤0.01% |
15,922
-84,621
| -84% | -$255K |
|
1004
Annexon
ANNX
$883M
| $34.5K | ﹤0.01% |
+17,732
| New | +$59K |
|
1005
Biomea Fusion
BMEA
$92.1M
| $34.2K | ﹤0.01% |
+16,077
| New | +$54.8K |
|
1006
Expensify
EXFY
$225M
| $33.5K | ﹤0.01% |
+11,052
| New | +$38.4K |
|
|
CVAC
1007
DELISTED
CureVac
CVAC
| $33.1K | ﹤0.01% |
+11,872
| New | +$41.3K |
|
1008
Standard BioTools
LAB
$310M
| $32.9K | ﹤0.01% |
+30,310
| New | +$42.6K |
|
1009
Perspective Therapeutics
CATX
$342M
| $32.4K | ﹤0.01% |
+15,158
| New | +$45.5K |
|
1010
AbCellera Biologics
ABCL
$2.85B
| $32.4K | ﹤0.01% |
14,584
-21,872
| -60% | -$62.7K |
|
|
SVC
1011
Service Properties Trust
SVC
$1.05B
| $32.2K | ﹤0.01% |
2,465
-31,575
| -93% | -$428K |
|
|
NB
1012
NioCorp Developments
NB
$793M
| $32K | ﹤0.01% |
+16,166
| New | +$32.5K |
|
|
EB
1013
DELISTED
Eventbrite
EB
| $31.1K | ﹤0.01% |
14,751
+3,902
| +36% | +$11.7K |
|
1014
Wheels Up
UP
$191M
| $30.5K | ﹤0.01% |
+1,518
| New | +$41.8K |
|
1015
CareCloud
CCLD
$102M
| $30K | ﹤0.01% |
+21,731
| New | +$64K |
|
1016
Fossil Group
FOSL
$317M
| $29.6K | ﹤0.01% |
25,602
-97
| -0.4% | -$152 |
|
1017
Cerus
CERS
$508M
| $28K | ﹤0.01% |
+20,200
| New | +$33.8K |
|
1018
Erasca
ERAS
$6.29B
| $27.9K | ﹤0.01% |
+20,366
| New | +$35K |
|
1019
BranchOut Food
BOF
$62.9M
| $26.4K | ﹤0.01% |
+10,803
| New | +$22.2K |
|
1020
Kyverna Therapeutics
KYTX
$480M
| $26.2K | ﹤0.01% |
+13,552
| New | +$40K |
|
1021
C4 Therapeutics
CCCC
$400M
| $25.5K | ﹤0.01% |
+16,009
| New | +$47.8K |
|
|
SLRN
1022
DELISTED
ACELYRIN
SLRN
| $25.3K | ﹤0.01% |
+10,246
| New | +$24.4K |
|
1023
Alto Neuroscience
ANRO
$1.1B
| $24.7K | ﹤0.01% |
+11,402
| New | +$40.8K |
|
|
VTYX
1024
DELISTED
Ventyx Biosciences
VTYX
| $24.5K | ﹤0.01% |
+21,148
| New | +$36.3K |
|
1025
Commercial Vehicle Group
CVGI
$134M
| $24.4K | ﹤0.01% |
21,061
-289
| -1% | -$559 |
|
Similar funds
BCI
VA
PI
UE
LC
DWM
ERSOT
Quadrature Capital's Q1 2025 Portfolio in Review
As of Q1 2025, Quadrature Capital held 1,566 positions worth $4.51B, down 9.6% from $4.99B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Quadrature Capital withdrew a net $244M in Q1 2025, closing 534 positions and reducing 242 holdings. Its most notable exit was NVIDIA, an estimated $182M position sold in full.
By sector, the portfolio is most concentrated in Technology at 14% of assets, up from 14% a quarter earlier, followed by Financials and Industrials.
Against the trend, Quadrature Capital opened a new position in Stellantis worth $75.4M.
- Quadrature Capital's largest Q1 2025 buy was Stellantis: 6,785,857 shares worth $75.4M.
- Quadrature Capital added most to Broadcom in Q1 2025, an estimated $243M increase.
- Quadrature Capital's biggest Q1 2025 reduction was UnitedHealth, cutting an estimated $111M.
- Quadrature Capital fully exited NVIDIA in Q1 2025, selling an estimated $182M.
- Quadrature Capital's ten largest holdings make up 25% of its $4.51B portfolio in Q1 2025.
- Quadrature Capital opened 582 new positions and closed 534 in Q1 2025.
- Quadrature Capital's portfolio value fell 9.6% quarter-over-quarter to $4.51B.
Based on Quadrature Capital's 13F filing for Q1 2025, filed 13 May 2025.